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Finding a cell that reprograms in a nonstochastic manner without genetic manipulation has proven
elusive. In this issue, Guo et al. report the identification of a cell defined by an ultrafast cycle whose
progeny reprogram in a synchronous and rapid manner.Figure 1. Privileged Reprogramming in
Granulocyte Monocyte Progenitor Lineages
Induced pluripotency is nonstochastic in a subset
of isolated granulocyte monocyte progenitors
(GMPs) that are recognized by an ultrafast cell
cycle in the founder cell. The ultrafast cycle is
independent of Yamanaka factor expression or
genetic manipulation, and nearly all of the privi-
leged cell’s progeny will express Oct4:GFP.The discovery of induced pluripotency
has revealed the remarkable plasticity of
differentiated cells. However, the ineffi-
ciency of this process has presented
considerable barriers to defining the rules
of reprogramming. Competing hypoth-
eses have been developed to account
for bottlenecks. An elite model proposes
that only a subset of determined founder
cells exist within a population and have
the potential to yield reprogrammed prog-
eny. A stochastic model allows for all cells
within a population to initiate reprogram-
ming, albeit with few successful events.
Genetic strategies have been used to
identify roadblocks that inhibit deter-
ministic reprogramming. Recently, it
has been shown that depletion of the
nucleosome and remodeling deacetylase
(NuRD) complexmemberMbd3 allows for
near 100% reprogramming efficiency
(Rais et al., 2013). In this issue, Guo and
colleagues apply a different approach to
this problem. Using in vitro live-cell
imaging of clonal granulocyte monocyte
progenitor (GMP) lineages, they identify
a ‘‘privileged’’ cell that is not bound
by intrinsic reprogramming bottlenecks
(Guo et al., 2014).
Previous studies by this group estab-
lished the technical capacity to image
reprogramming at minute intervals using
GMPs from mice that carry an Oct4:GFP
allele (Megyola et al., 2013). The authors
now use this technology to search for a
cell that can be reprogrammed by a deter-
ministic mechanism. The ideal properties
of this cell are progeny that synchronously
transition to the pluripotent state with a
short latent period following Yamanaka
factor induction. Amazingly, the re-
construction of complete GMP lineages
from successful reprogramming events
reveals a subset of cells with these prop-
erties. The privileged cells and all of theirprogeny adopt the pluripotent state within
48 hr of transgene expression. The high-
content data yielded by cell imaging of
the somatic GMPs revealed a striking
phenotype. The cycle time of the first
division in the privileged founders was
an ultrafast 8 hr, significantly shorter
than the derivative pluripotent cells them-
selves (Figure 1).
To extend their finding, the authors
show that the ultrafast cycle can be
induced by cytokine stimulation of
the relatively slow cycling LinKit+Sca+
hematopoietic stem cell, resulting in priv-
ileged reprogramming. Surprisingly, Guo
et al. also show that the ultrafast pheno-
type is a function of Yamanaka factor
expression in mouse embryonic fibro-
blasts (MEFs). This is consistent with a
previous study using live-cell imaging of
reprogramming MEFs that reveals a rapid
increase in proliferation rates of founders
(Smith et al., 2010). Inhibition of the p53
tumor suppressor in clonal B cells also
promotes proliferation and enhances
reprogramming (Hanna et al., 2009). Guo
et al. argue that depletion of p53 in
MEFs promotes the emergence of the
ultrafast cycling population and that this
specifically accounts for the increased
efficiency of reprogramming. Rapid rates
of proliferation have been positively cor-
related with reprogramming before. How-
ever, the key finding reported here is that
you can reprogram somatic cells by a
deterministic mechanism independent of
any other genetic manipulation.
The hematopoietic lineage has been
exploited previously to show that primitive
cells reprogram more efficiently than their
differentiated progeny (Eminli et al., 2009).
This is consistent with epigenetic models
of development in which cell identity
is increasingly restricted by changes
in chromatin status. These new resultsCell 156,show that the privileged cell is not the
hematopoietic stem cell (HSC); rather, it
is a restricted progenitor. Molecular char-
acterization reveals elevated levels of the
cell-cycle inhibitor Cdkn1c (p57) in the
slow cycling HSCs versus the GMP cells.
Reduction of p57 levels specifically leads
to an increase in HSC reprogramming
efficiencies. These results are consistent
with other recent results linking the
action of cell-fate regulators to cell-cycleFebruary 13, 2014 ª2014 Elsevier Inc. 631
inhibitors. A deeper understanding of
the way that cell-cycle inhibitors are
controlled in somatic lineages may have
important implications in regenerative
medicine.
The restoration of function in diseased
tissue is the major goal of regenerative
medicine. There is significant interest in
leveraging the rules of cellular reprogram-
ming to inform clinical strategies. To regu-
late homeostasis, resident somatic stem
and progenitor cells must maintain tissue
for the life of the organism while allowing
response to acute injury. In the gut epithe-
lium, differentiated cells are constantly re-
placed by progenitors in the intestinal
crypts. Distinct lineages (secretory and
enterocyte) are specified by D-like ligand
mediated lateral inhibition. Strikingly, the
chromatin of all progenitor cells in the
crypt, including the Lgr5+ stem cell, is
very similar and broadly permissive based
on enhancer mapping (Kim et al., 2014).
This design allows for Notch-based cell
interactions and specific transcription
factors to efficiently specify fates without
the requirement for dramatic epigenetic
changes. In another experiment, indivi-
dual Yamanaka factors have different ef-
fects in the intestinal crypt. Whole-animal
overexpression of Sox2 targets the Lgr5+
cell in the gut, inducing expansion of the632 Cell 156, February 13, 2014 ª2014 Elseventire crypt, whereas Oct4 overexpres-
sion only expands the transit-amplifying
cell (Kuzmichev et al., 2012). Consistent
with a profound role for Sox2 in specifying
cell identity, activation of the endogenous
gene is associated with a late determin-
istic phase of reprogramming (Buganim
et al., 2012). It will be interesting to see
how the different Yamanaka factors act
in the privileged cell reported by Guo et al.
The results presented by Guo et al.
force us to consider the behaviors of
different cells in a lineage. Recent work
shows that oncogenic Nras increases
competiveness through a bimodal effect
on early hematopoietic precursor cells,
increasing the self-renewal potential of
one subset while increasing the prolifera-
tion of another (Li et al., 2013). This occurs
through a Stat5-dependent signaling
mechanism, but we don’t know exactly
how differences in this early cellular
compartment generate these two out-
comes. These results remind us that
watching the behavior of cells in the
hematopoietic lineage can reveal power-
ful new biological insights.REFERENCES
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